EUVIMEDEUVIMED entdecken
Crossref

Ursolic Acid Conjugates: A New Frontier in Anticancer Drug Development

Riham M Bokhtia iD, Ashley M Pham, Kunj Bihari Gupta iD, Shamta S Warang, Natasha Venugopal iD, Rajeev Shakuja, Payaningal R Somanath, Fang Liu, Yi Chang Jeon, Guilherme J Guimaraes, Michael G Bartlett, Muthusamy Thangaraju und 2 weitere

ChemBioChem · 2024

DOI: 10.1002/cbic.202400376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2024. Verfasst von Riham M Bokhtia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt. Hauptthemen laut MEDLINE: Ursolic Acid, Triterpenes, Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Augusta University Provost's office, Translational Research Program of the Department of Medicine, Medical College of Georgia at Augusta University, Dr. J. Harold Harrison Endowment Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New Ursolic Acid (UA) conjugates were synthesized using optimized synthetic protocols through the molecular hybridization approach at C‐3 and C‐28. This resulted in the targeted molecules being produced in good yields. Some of the synthesized conjugates showed significantly relevant bioactivity against mammalian cells and in animal models of cancers. Selected UA conjugates were tested against bladder and breast cancer cell lines. The conjugates showed moderate to significantly enhanced antiproliferative activities against Triple Negative Breast Cancer (TNBC; MDA‐MB 231), which is an aggressive tumor making up about 10–15 % of all breast cancers and bladder (T24 and 5637) cancer cell lines. These properties were superior to the parent UA. Among all the synthesized compounds, 18 c and 18 d have exhibited promising antiproliferative and cytotoxic properties against all tested cancer cell lines. However, 18 d has proved to be exceptionally selective for cancer cell lines, showing more cytotoxicity towards them than normal epithelial cells (MCF‐12A). Compound 18 d has demonstrated cytotoxicity against tumor cells, including those intrinsically resistant to chemotherapy drugs such as 2‐difluoro‐deoxy cytidine (Gemcitabine). The activity of the UA conjugates on tumor cells was mediated by multiple cytotoxic mechanisms, including drug‐induced cytotoxic autophagy and programmed cell death, indicating a novel possibility of combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursolic AcidTriterpenesAntineoplastic AgentsCell ProliferationDrug Screening Assays, AntitumorHumansCell Line, TumorAnimalsDrug DevelopmentApoptosisMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

Bladder cancerBreast cancerComputational studiesMolecular hybridizationNatural productSynthesis

Substanzen

Ursolic AcidTriterpenesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
  • Department of Chemistry and Biochemistry, Augusta University, Augusta, GA, 30912, USA.
  • Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.
  • Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, 17033, USA.
  • Department of Chemistry, Birla Institute of Technology and Science, Pilani, India.
  • Clinical and Experimental Therapeutics, University of Georgia, Charlie Norwood VAMedical Center, Augusta, GA.

ORCID-Profile: Riham M Bokhtia, Kunj Bihari Gupta, Natasha Venugopal, Bal L Lokeshwar, Siva S Panda

Förderung

  • Augusta University Provost's office
  • Translational Research Program of the Department of Medicine, Medical College of Georgia at Augusta University
  • Dr. J. Harold Harrison Endowment Fund
  • Medical College of Georgia's new investigator and retention fund

Zitieren

APA

Bokhtia, R. M., Pham, A. M., Bihari Gupta, K., Warang, S. S., Venugopal, N., Shakuja, R., Somanath, P. R., Liu, F., Chang Jeon, Y., Guimaraes, G. J., Bartlett, M. G., Thangaraju, M., Lokeshwar, B. L., & Panda, S. S. (2024). Ursolic Acid Conjugates: A New Frontier in Anticancer Drug Development. ChemBioChem. https://doi.org/10.1002/cbic.202400376

Vancouver

Bokhtia RM, Pham AM, Bihari Gupta K, Warang SS, Venugopal N, Shakuja R, et al. Ursolic Acid Conjugates: A New Frontier in Anticancer Drug Development. ChemBioChem. 2024. doi:10.1002/cbic.202400376

BibTeX
@article{Bokhtia2024,
  author = {Bokhtia, Riham M and Pham, Ashley M and Bihari Gupta, Kunj and Warang, Shamta S and Venugopal, Natasha and Shakuja, Rajeev and Somanath, Payaningal R and Liu, Fang and Chang Jeon, Yi and Guimaraes, Guilherme J and Bartlett, Michael G and Thangaraju, Muthusamy and Lokeshwar, Bal L and Panda, Siva S},
  title = {Ursolic Acid Conjugates: A New Frontier in Anticancer Drug Development},
  journal = {ChemBioChem},
  year = {2024},
  doi = {10.1002/cbic.202400376}
}
Kostenlos starten →